MooreM.J., GoldsteinD., HammJ.: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).ASCO GI Miami, abst 77, 2005.
2.
MitchellE.P., AlbertsS.R., SchwartzM.A.: Highdose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200.ASCO GI Miami, abst 169a, 2005.
3.
De GramontA., BoniC., NavarroM.: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years, ASCO GI Miami, abst 167, 2005.
4.
GreenE., SargentD.J., GoldbergR.M., GrotheyA.: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741.ASCO GI Miami, abst 182, 2005.
5.
HallerD., AlbertsS., AdamR.: ONCOSURGE: a therapeutic decision model to optimize the management of colorectal liver metastases.ASCO GI Miami, abst 162, 2005.
